Meeting Banner
Abstract #1156

Predictive Value of Magnetic Resonance Spectroscopic Imaging during Anti-angiogenic Treatment in Recurrent Glioblastoma

Daniel Kim1,2, Jorg Dietrich3, Elizabeth Gerstner2,3, Julian He1, Otto Rapalino1, Yangming Ou4, Yi-Fen Yen1,2, Mark Vangel1, Ovidiu Andronesi1,2, Isabel Arrillaga3, Deborah Forst3, Jayashree Kalpathy-Cramer 1,2, Bruce Rosen1,2, Tracy Batchelor3, Ramon Gilberto Gonzalez1, and Eva-Maria Ratai1,2

1Radiology, Massachusetts General Hospital, Boston, MA, United States, 2Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States, 3Neurology, Massachusetts General Hospital, Boston, MA, United States, 4Radiology, Boston Children's Hospital, Boston, MA, United States

Our study examines the use of MR Spectroscopic Imaging to predict treatment response to anti-angiogenic therapy for recurrent glioblastoma patients. Our data demonstrated that early changes at 1-3 days, 4 weeks, and 6 weeks in Cho/NAA, Lac/nCr, and Lac/NAA can be predictive of 9-months survival outcomes in patients with recurrent glioblastoma treated with bevacizumab. Theses preliminary findings suggest that early changes in certain metabolic ratios can be useful markers for predicting therapeutic response to bevacizumab treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here